# US 6,727,078 B2 · EIAV p26 deletion vaccine and diagnostic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,078 B2
- Document ID: US6727078B2
- Status: Granted
- Kind: B2
- Application number: 10/125,087
- Filed: 2002-04-18
- Published: 2003-02-06
- Granted: 2004-04-27
- Earliest claimed: 2000-09-09
- Assignees: Akzo Nobel N.V.; University of Pittsburgh—Of the Commonwealth System of Higher Education
- Inventors: Ronald Montelaro; Jodi Craigo; Charles Issel; Bridget Puffer; Kristina J. Hennessey; Karen K. Brown
- Web page: https://patentgrep.com/patent/US6727078B2

## CPC

- C07K 14/005: from viruses
- A61P 31/18: for HIV
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2740/15022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Preferably said composition encompasses at least one deletion in a lentivirus which provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease without converting to a seropositive status on the Coggin's Test or any other test wich measures p26.

## Claims

### Claim 1

A method of preparing a lentivirus immunogenic composition comprising:
1) deleting all or a portion of a gag gene from the lentivirus, whereby the resulting gag gene-deleted lentivirus lacks the ability to express a capsid antigen;
2) transfecting a tissue culture with the resulting gene-deleted lentivirus to produce a persistently transfected cell culture;
3) growing the persistently transfected cell culture;
4) harvesting the persistently transfected cell culture;
5) optionally inactivating the harvested cell culture; and, optionally adjuvanting the harvested cell culture.

### Claim 2 (depends on 1)

The method of claim 1 wherein the step of deleting all or a portion of the gag gene comprises using specific restriction endonucleases to remove all or part of the gag gene.

### Claim 3 (depends on 1)

The method of claim 1 wherein the step of deleting all or a portion of the gag gene comprises PCR ligation and PCR cloning.

### Claim 4 (depends on 1)

The method of claim 1 wherein the step of deleting all or a portion of the gag gene comprises deleting all or a portion of the gene encoding the Capsid Antigen.

### Claim 5 (depends on 1)

The method of claim 1 wherein the step of deleting all or a portion of the gag gene comprises inserting a stop codon.

### Claim 6 (depends on 5)

The method of claim 5 wherein stop codon is inserted at the 5′ end.

### Claim 7 (depends on 1)

The method of claim 1 further comprising the step of inserting a foreign gene sequence into the gene-deleted portion.

### Claim 8 (depends on 7)

The method of claim 7 wherein the foreign gene sequence is selected from the group consisting of herpes virus, Arteritis virus, Encephalomyelitis virus, influenza, encephalitis, toxoplasma, neospora, streptococcus, and clostridium.

### Claim 9 (depends on 7)

The method of claim 7 wherein the foreign gene sequence is inserted by PCR ligation and PCR cloning.

### Claim 10 (depends on 1)

The method of claim 1 wherein the step of deleting all or a portion of the gag gene comprises a deletion of one or more regions selected from the group consisting of a portion of the gag gene, a gene regulating expression of the gag gene, and the insertion of a stop codon in a gene effecting the expression of the gag gene.

### Claim 11 (depends on 1)

The method of claim 1 wherein the lentivirus is Equine Infectous Anemia Virus (EIAV).

### Claim 12 (depends on 1)

The method of claim 1 further comprising the steps of transfecting the cell culture with a transfecting agent and cloning the cell culture when the EIAV is unable to grow in vitro.
